Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of ZE74-0282 in Healthy Volunteers
NCT07527221Phase 1Recruiting
- Sponsor
- Eilean Therapeutics
- Start
- Apr 2026
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ZE74-0282 (8 cohorts), sponsored by Eilean Therapeutics. Primary endpoints: Incidence of Adverse Events and Serious Adverse Events, Change from Baseline in body weight and 9 more. Started Apr 2026; status: recruiting.
02
Drugs
ZE74-0282
Beyond the preview
Go deeper on NCT07527221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07527221.